BR9407182A - Composição imunogênica processo de preparo de composição não-imunopotencializadora imunogênica processo para determinar a presença de anticorpos estojo para diagnóstico para determinar a presença de anticorpos e virus sincicial respiratório humano inativado purificado - Google Patents

Composição imunogênica processo de preparo de composição não-imunopotencializadora imunogênica processo para determinar a presença de anticorpos estojo para diagnóstico para determinar a presença de anticorpos e virus sincicial respiratório humano inativado purificado

Info

Publication number
BR9407182A
BR9407182A BR9407182A BR9407182A BR9407182A BR 9407182 A BR9407182 A BR 9407182A BR 9407182 A BR9407182 A BR 9407182A BR 9407182 A BR9407182 A BR 9407182A BR 9407182 A BR9407182 A BR 9407182A
Authority
BR
Brazil
Prior art keywords
immunogenic
antibodies
virus
immunogenic composition
respiratory syncytial
Prior art date
Application number
BR9407182A
Other languages
English (en)
Inventor
Sonia E Sanhueza
Mary Elizabeth Ewasyshyn
Michel Henri Klein
Original Assignee
Connaught Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connaught Lab filed Critical Connaught Lab
Publication of BR9407182A publication Critical patent/BR9407182A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18551—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
BR9407182A 1993-08-06 1994-08-04 Composição imunogênica processo de preparo de composição não-imunopotencializadora imunogênica processo para determinar a presença de anticorpos estojo para diagnóstico para determinar a presença de anticorpos e virus sincicial respiratório humano inativado purificado BR9407182A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10274293A 1993-08-06 1993-08-06
PCT/CA1994/000425 WO1995004545A1 (en) 1993-08-06 1994-08-04 Inactivated respiratory syncytial viral vaccines

Publications (1)

Publication Number Publication Date
BR9407182A true BR9407182A (pt) 1996-09-17

Family

ID=22291469

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9407182A BR9407182A (pt) 1993-08-06 1994-08-04 Composição imunogênica processo de preparo de composição não-imunopotencializadora imunogênica processo para determinar a presença de anticorpos estojo para diagnóstico para determinar a presença de anticorpos e virus sincicial respiratório humano inativado purificado

Country Status (15)

Country Link
US (1) US7083795B1 (pt)
EP (1) EP0714306B1 (pt)
JP (1) JP4053587B2 (pt)
KR (1) KR100402379B1 (pt)
CN (1) CN1103603C (pt)
AT (1) ATE164313T1 (pt)
AU (1) AU677090B2 (pt)
BR (1) BR9407182A (pt)
CA (1) CA2167274C (pt)
DE (1) DE69409243T2 (pt)
DK (1) DK0714306T3 (pt)
ES (1) ES2113670T3 (pt)
GR (1) GR3026619T3 (pt)
RU (1) RU2142817C1 (pt)
WO (1) WO1995004545A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4243491A1 (de) * 1992-12-22 1994-06-23 Behringwerke Ag Verfahren zur Reinigung und Anreicherung von Rubella-Virus
BR112013000345B1 (pt) * 2010-07-07 2021-11-23 Artificial Cell Technologies, Inc Composição compreendendo partículas contendo epítopos de rsv
EP3822347A4 (en) * 2018-07-06 2022-04-27 Xiamen University PROCEDURE FOR INACTIVATION AND STORAGE OF RESPIRATORY SYNCYTIAL VIRUS
JP2023501693A (ja) * 2019-12-10 2023-01-18 レプリゲン・コーポレーション ウイルスベクターの調製方法
EP4281065A1 (en) 2021-01-20 2023-11-29 Alto Neuroscience, Inc. Enhancement of camp signaling as a combination drug strategy for the treatment of depression and related conditions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1188985A (en) * 1980-07-01 1985-06-18 Edward J. Stott Production of viral antigens
US4591505A (en) * 1982-04-14 1986-05-27 New York Blood Center, Inc. Process for inactivating hepatitis B virus
US4664912A (en) 1984-10-01 1987-05-12 Wiktor Tadeusz J Process for the large scale production of rabies vaccine
US4790987A (en) * 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
US4732683A (en) * 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
US5200179A (en) * 1987-09-28 1993-04-06 Beecham Group P.L.C. Vaccine
AU624081B2 (en) * 1987-09-28 1992-06-04 Pfizer Inc. A vaccine substantially free from live viruses or bacteria
US5223254A (en) * 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
GB8914968D0 (en) 1989-06-29 1989-08-23 Connaught Lab Production of virus and purification of viral envelope proteins for vaccine use
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus

Also Published As

Publication number Publication date
RU2142817C1 (ru) 1999-12-20
DE69409243T2 (de) 1998-08-06
JP4053587B2 (ja) 2008-02-27
US7083795B1 (en) 2006-08-01
CN1133013A (zh) 1996-10-09
ATE164313T1 (de) 1998-04-15
CA2167274A1 (en) 1995-02-16
GR3026619T3 (en) 1998-07-31
AU677090B2 (en) 1997-04-10
KR960703618A (ko) 1996-08-31
JPH09501912A (ja) 1997-02-25
ES2113670T3 (es) 1998-05-01
CN1103603C (zh) 2003-03-26
EP0714306B1 (en) 1998-03-25
DE69409243D1 (de) 1998-04-30
DK0714306T3 (da) 1998-10-19
WO1995004545A1 (en) 1995-02-16
AU7380194A (en) 1995-02-28
CA2167274C (en) 2007-11-27
EP0714306A1 (en) 1996-06-05
KR100402379B1 (ko) 2004-03-24

Similar Documents

Publication Publication Date Title
WO2004001007A3 (en) Buffered formulations for concentrating antibodies and methods of use thereof
IT1237764B (it) Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
HU229368B1 (en) Novel vaccine composition
ES2178015T3 (es) Procedimiento de preparacion de isomeros de formoterol opticamente puros.
ATE197314T1 (de) Verfahren zum vermehren des das reproduktions- und atemwegs-syndrom verursachenden schweinevirus und dessen verwendung als impfstoff.
DK0610250T3 (da) Vaccine med porcint reproduktivt respiratorisk syndrom og diagnose heraf
DK0461177T3 (da) Humant intra-acrosomalt spermantigen til anvendelse i en svangerskabsforebyggende vaccine
ATE36956T1 (de) Verfahren zu herstellung von lebenden, adjuvierten impfstoffen und so erhaltende lebende, adjuvierte impfstoffe.
ATE38988T1 (de) Imidazolylphenyl-tetrahydropyridazine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
ATE130198T1 (de) Herstellung eines virus und reinigung von virenüberzugsproteinen zur impfstoffverwendung.
BR9407182A (pt) Composição imunogênica processo de preparo de composição não-imunopotencializadora imunogênica processo para determinar a presença de anticorpos estojo para diagnóstico para determinar a presença de anticorpos e virus sincicial respiratório humano inativado purificado
ATE77957T1 (de) Peptid-zusammensetzung fuer die herstellung von malaria-impfstoff, sowie fuer die vorbereitung von diagnostischen einzelteilen fuer den nachweis von malaria-aehnlichen krankheiten.
NO169820C (no) Fremgangsmaate for fremstilling av en mastittvaksine
HK1058948A1 (en) Malria plasmodium antigen polypeptide se36, method of purifying the same and vaccine and diagnostic with the use of the thus obtained antigen
FI892877A (fi) Foerfarande foer tilldelning av ostframstaellningsegenskaper pao oeverhettad mjoelk foer framstaellning av loepeostar.
Black et al. The evaluation of hypersensitivity tests in cattle after foot-and-mouth disease vaccination
NO175846C (no) Fremgangsmåte for å oppnå et immunogen
DE69515053T2 (de) Verfahren zur herstellung von furosemide
ATE12649T1 (de) Optisch aktives dipeptide, seine pharmazeutisch vertraeglichen salze, verfahren zur herstellung und diese enthaltende pharmazeutische praeparate.
World Health Organization SURVEILLANCE OF ACUTE RESPIRATORY INFECTIONS: Investigation of an Outbreak of Acute Upper Respiratory Infection
DE50008782D1 (de) VERFAHREN ZUR HERSTELLUNG VON WESPENGIFT-ALLERGENEN MIT VERMINDERTER IgE-REAKTIVITÄT
JPS56115724A (en) Prophilaxis and remedy for avian infectious coryza
Miller The Evaluation of Measles Vaccine as a Protective Measure: Clinical Trials of Measles Vaccines in Britain
World Health Organization MARBURG DISEASE= MALADIE DE MARBURG
World Health Organization JAPANESE ENCEPHALITIS

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
FA8 Dismissal: dismissal - article 36, par. 1 of industrial property law